In the individualized treatment of T2DM, these studies on the effectiveness of GLP-1-RAs, especially newer ones such as semaglutide, emphasize their potential as effective strategies, particularly for patients who prioritize weight loss and cardiovascular risk reduction in addition to glycemic management [70,71]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.